Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 5/20 | 0.43 |
| ▸ | ACE | P12821 | 5/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18263621 | 1.00 | MAPT (0.60) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL4632742 | 0.96 | MAPT (0.56) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL17287153 | 0.93 | PTGS1 (0.57) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL30065558 | 0.93 | PTGS1 (0.54) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL29774451 | 0.88 | PTGS1 (0.52) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL14647811 | 0.87 | MAPT (0.54) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL236405 | 0.85 | PTGS1 (0.67) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL20787749 | 0.85 | PTGS1 (0.67) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL19579377 | 0.85 | PTGS1 (0.58) | MAPTPTGS2BLMKDM4ETHRB | |
| SCHEMBL18862364 | 0.84 | MAPT (0.53) | MAPTPTGS2BLMKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124166-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2026-05-07 | — | — | US | claimed |
| EP-4615434-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2025-09-17 | — | — | EP | claimed |
| WO-2024099883-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-05-16 | — | — | WO | claimed |
| US-11730711-B2 | Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels | BAYLOR COLLEGE OF MEDICINE (US) | 2023-08-22 | — | — | US | claimed |
| WO-2021232041-A1 | N-ACETYLCYSTEINE AND GLYCINE FOR TREATMENT OF COVID-19 AND POST COVID-19 SYMPTOMS | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-18 | — | — | WO | claimed |
| US-20210244696-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | BAYLOR COLLEGE OF MEDICINE | 2021-08-12 | — | — | US | claimed |
| US-10952982-B2 | Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2021-03-23 | — | — | US | claimed |
| US-20180161297-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | Société des Produits Nestlé S.A. (CH) | 2018-06-14 | — | — | US | claimed |
| EP-3302459-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | Baylor College of Medicine (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016191468-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | BAYLOR COLLEGE OF MEDICINE (US) | 2016-12-01 | — | — | WO | claimed |
| US-20260124166-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2026-05-07 | — | — | US | disclosed |
| US-12496285-B2 | Compositions and methods using at least one glycine or derivative thereof, at least one N-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or NAD+ precursor | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-12-16 | — | — | US | disclosed |
| EP-4615434-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | Société des Produits Nestlé S.A. (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-12186292-B2 | Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-01-07 | — | — | US | disclosed |
| US-20240410864-A1 | METHOD FOR DETECTING AND/OR QUANTIFYING MOOD DISORDER AND/OR IMPROVEMENTS OF THE MOOD DISORDER STATUS USING CONJUGATED BILE ACIDS AS BIOMARKER AND IMPROVED METHODS AND COMPOSITIONS THEREOF | NESTLE SA (CH) | 2024-12-12 | — | — | US | disclosed |
| US-20100048587-A1 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090105150-A1 | Angiotensin derivatives | PROTHERICS MEDICINES DEVELOPMENT LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-7378489-B1 | Angiotensin derivatives | PROTHERICS MEDICINES DEVELOPMENT LIMITED (GB) | 2008-05-27 | — | — | US | disclosed |
| EP-0536231-A1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES, COMPOUNDS OBTAINED FROM SAID PROCESS AND AN INTERMEDIATE USEFUL FOR THE PREPARATION THEREOF. | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-04-14 | — | — | EP | disclosed |
| WO-1992000320-A1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES, COMPOUNDS OBTAINED FROM SAID PROCESS AND AN INTERMEDIATE USEFUL FOR THE PREPARATION THEREOF | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124166-A1 | COMPOSITIONS AND METHODS USING GLYCINE TO REDUCE BIOLOGICAL AGE OF AN ADULT ANIMAL | GLS, AGER, LRRK2 | MAPT 1402/4885PTGS2 108/4885BLM 4473/4885 |
| US-20090105150-A1 | Angiotensin derivatives | AGTR1, AGTR2, AGT | MAPT 2409/4885PTGS2 779/4885BLM 2677/4885 |
| US-20100048587-A1 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, CBS, SLC7A11 | MAPT 2979/4885PTGS2 2922/4885BLM 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.